Temasek and ADIA Invest in Sironax’s Series B Round

Posted on 08/03/2022

China-based Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research.

Sironax completed a US$ 200 million Series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek Holdings, Invus Group, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture Partners and lead investors from previous financings. In addition to the co-leads, new investors include MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund as well as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA). With the closing of this round, Sironax has raised over US$ 300 million to date.

Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline of potential best- and first-in-class candidates for age-related degenerative diseases.

Keywords: Fidelity Management & Research (Fidelity Investments).

    Get News, People, and Transactions, Delivered to Your Inbox